Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevLett.122.059804 | DOI Listing |
JAMA Netw Open
January 2025
University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Importance: A substantial number of individuals worldwide experience long COVID, or post-COVID condition. Other postviral and autoimmune conditions have a female predominance, but whether the same is true for long COVID, especially within different subgroups, is uncertain.
Objective: To evaluate sex differences in the risk of developing long COVID among adults with SARS-CoV-2 infection.
Cancer Treat Rev
January 2025
Upper Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Neuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving response no consensus exists on maintenance therapies and the results are inconsistent. This review examines the role of maintenance therapy following response to first-line chemotherapy in gastroenteropancreatic neuroendocrine carcinomas.
View Article and Find Full Text PDFImportance: Classification of persons with long COVID (LC) or post-COVID-19 condition must encompass the complexity and heterogeneity of the condition. Iterative refinement of the classification index for research is needed to incorporate newly available data as the field rapidly evolves.
Objective: To update the 2023 research index for adults with LC using additional participant data from the Researching COVID to Enhance Recovery (RECOVER-Adult) study and an expanded symptom list based on input from patient communities.
JAMA Netw Open
December 2024
Boston University Alzheimer's Disease Research Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
Importance: Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impacts (RHIs). Prior research suggests a dose-response association between American football play duration and CTE risk and severity, but this association has not been studied for ice hockey.
Objective: To investigate associations of duration of ice hockey play with CTE diagnosis and severity, functional status, and dementia.
Neurology
December 2024
From the Boston University Alzheimer's Disease Research Center and Chronic Traumatic Encephalopathy Center (M.U., E.N., S.D., B.A., N.S., A.S., J.P., J.D.C., D.D., B.D., L.G., B.H., D.K., N.K., R.C.C., V.E.A., R.A.S., T.D.S., Y.T., A.C.M., M.L.A., J.M.), Framingham Heart Study (R.B., A.C.M.), Departments of Pathology and Laboratory Medicine (J.D.C., T.D.S., A.C.M.), Neurology (B.D., B.H., D.K., R.C.C., R.A.S., A.C.M., M.L.A., J.M.), Psychiatry (L.G.), Radiology (L.G.), Ophthalmology (L.G.), and Biomedical Engineering (L.G.), Boston University Chobanian & Avedisian School of Medicine; Departments of Applied Social Sciences (S.W.C., D.R.) and Biomedical Engineering (L.G.), Boston University; Department of Biostatistics (F.T.-Z., Z.B., B.M., J.P., Y.T.), Boston University School of Public Health; Spaulding Rehabilitation Hospital (D.D.), Charlestown; Braintree Rehabilitation Hospital (B.D., D.K.); Department of Rehabilitation and Human Performance (K.D.-O.C.), Brain Injury Research Center, Department of Pathology (J.C.), Department of Artificial Intelligence & Human Health, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, and Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, NY; VA Boston Healthcare System (B.H., N.K., V.E.A., T.D.S., A.C.M.); Department of Neurosurgery (R.C.C.), Emerson Hospital, Concord; and VA Bedford Healthcare System (V.E.A., T.D.S., A.C.M.), MA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!